TRANSPOSABLE ELEMENTS IN NORMAL AND CANCER EPIGENOME
报告人： Ting Wang, Washington University Medical Schoo
时间：2018-07-03 14:00 ~ 15:00
地点：理科一号楼1304
Abstract:
Advances in next-generation sequencing platforms have reshaped the landscape of genomic and epigenomic research towards the understanding of roles of human transposable elements. It is now possible to map the epigenetic landscape of transposable element (TE) across many tissue and cell types as well as in diseases. In the presentation I will discuss tools developed for this purpose and present some results from investigating regulatory roles of transposable elements.
About the Speaker:
Dr. Ting Wang is the Loewentheil Distinguished Professor in Precision Medicine, Professor of Genetics, Computer Science and Engineering, and Biostatistics, and Director of Computational and Systems Biology Program at Washington University Medical School. Dr. Wang received undergraduate degree of Biochemistry and Molecular Biology from Peking University in 1997. He obtained a PhD in Computational Biology from Washington University, and was a Helen Hay Whitney Fellow at University of California Santa Cruz, before returning to Washington University to start his own lab in the Department of Genetics and the Center for Genome Sciences and Systems Biology. Dr. Wang’s research focuses on understanding genetic and epigenetic impact of transposable element on regulatory networks. He investigates epigenetic determinants of cell fates during normal development, disease development, and in evolution. He develops algorithms for identifying regulatory motifs and modules, and analytical and visualization technologies to integrate large genomic and epigenomic data. He invented the UCSC Cancer Genomics Browser, and the WashU Epigenome Browser as part of the NIH Roadmap Epigenome Project. He is the Principle Investigator of six NIH funded projects, including establishing two data centers for the 4D Nucleome Network and for environmental epigenomics. He is also funded by a research scholar grant from American Cancer Society to study DNA methylation of enhancers in cancer development.
